Last reviewed · How we verify
NCT07148557
A Study of Single Dose of LP-003 in Adolescent Subjects
Phase 1, PHASE2 trial testing LP-003 Dose 1 (Single) in Allergic Diseases in 6 participants. Participants enrolled and being followed up; not accepting new ones.
31 May 2026
Quick facts
| Lead sponsor | Longbio Pharma |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 October 2025 |
| Primary completion | 31 May 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- LP-003 Dose 1 (Single) — full drug profile →
- LP-003 Dose 2 (Single)
Conditions studied
- Allergic Diseases — all drugs for Allergic Diseases →
Sponsor
Longbio Pharma — full company profile →
Who can join
Adults 12 to 18, any sex, with Allergic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07148557
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LP-003 Dose 1 (Single)
Trials testing the same drug.
- NCT06294288 — A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants · Phase 1 · completed
Other recruiting trials for Allergic Diseases
Currently open trials in the same condition.
- NCT07415551 — Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1- · Phase 2 · recruiting
- NCT06547372 — Dietary Intervention on Atopy · NA · recruiting
Other Longbio Pharma trials
Trials by the same sponsor.
- NCT07363265 — Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease · Phase 2 · not yet recruiting
- NCT07313917 — A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyp · Phase 2 · not yet recruiting
- NCT07266155 — Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) · Phase 2 · not yet recruiting
- NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
- NCT07212426 — Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients. · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07148557 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Longbio Pharma
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07148557.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing